Abelacimab (MAA868) is a fully human thrombin. Abelacimab can be used in thromboembolic disease studies[1][2].
Abelacimab (MAA868) (0.0001-1 μM) 以浓度依赖的方式延长凝血时间并减少人血浆中的凝血酶数量[1]。
Abelacimab (MAA868) (s.c., 3-30 mg/kg, on day 1, 85, 114) 在食蟹猴中表现出强烈和持续的抗凝血作用，显着延长 aPTT，且具有较好的安全性，未观察到显着的毒性发现或出血迹象[1]。
Abelacimab (MAA868) (i.v., 0.6 mg/kg) 在氯化铁诱导的血栓形成 FXI-/- C57BL/6 小鼠模型中表现出良好的抗凝血活性，以防止颈动脉阻塞[1]。
[1]. Alexander W Koch, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019 Mar 28;133(13):1507-1516.
[2]. Elena Campello, et al. Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. J Clin Med. 2022 Oct 26;11(21):6314.